DRI Healthcare Trust ("DRI Healthcare") today commented on Viridian Therapeutics, Inc.'s ("Viridian") recently announced ...

- First approved treatment for thyroid eye disease (TED) with labeling that includes data for both active and chronic TED - - In two pivotal phase 3 clinical trials, Lumvoa treatment showed rapid, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Viridian Therapeutics has spent years moving its thyroid eye disease (TED) hopeful, veligrotug, through clinical trials and is now at the FDA’s doorstep, with an approval decision expected next month.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

May 5 (Reuters) - Viridian Therapeutics (VRDN.O), opens new tab said on Tuesday its experimental thyroid eye disease drug met the main goal of a late-stage trial in chronic ‌patients, sending its ...

A second phase 3 trial of Viridian Therapeutics’ anti-IGF-1R antibody has hit its primary endpoint as the company prepares to file for FDA approval next year and challenge Amgen for a blockbuster ...

Viridian Therapeutics (VRDN) remains a 'Sell' as both lead TED assets underperform versus Amgen’s Tepezza, with limited product differentiation. Recent Phase 3 results for elegrobart (VRDN-003) and ...

Commodore Capital exited 3,200,000 shares of Viridian Therapeutics. As a result, the net position value decreased by $69.06 million due to the complete share sale. The position was previously 3.4% of ...

Shares of Viridian Therapeutics, Inc. (VRDN), have advanced 29% since my last update in December 2024 but are still down 35% since my first published article on Seeking Alpha. The last few years were ...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potentially best-in-class medicines for ...

Viridian Therapeutics reached a deal for up to $300 million in financing and accelerated the timelines for the submission of a biologics license application and topline data readouts from a late-stage ...